- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about NVS
Recent news which mentions NVS
US Stocks On Track For Nervous Start As Traders Go Fed Watching: AMD Earnings Calm Investors
February 01, 2023
From Benzinga
Novartis Reports Mixed Bag Q4 Earnings, Forecasts Higher Sales, Profits Ahead Of Sandoz Spin-Off
February 01, 2023
Tickers
NVS
From Benzinga
Earnings Scheduled For February 1, 2023
February 01, 2023
From Benzinga
Novartis posts lower sales and profit on generic competition, but boosts 2022 dividend
February 01, 2023
Tickers
NVS
From MarketWatch
7 CRISPR Stocks With the Best Long-Term Potential
January 30, 2023
From InvestorPlace
Philips Reports Q4 Earnings, To Lay Off Additional Employees This Year, Shares Jump
January 30, 2023
From Benzinga
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
January 29, 2023
From Benzinga
Could This Be Novartis' Next Blockbuster Medicine?
January 27, 2023
From Motley Fool
From Benzinga
3 Drug Stocks With Promising Pipelines for 2023
January 23, 2023
From InvestorPlace
From Benzinga
Analyst Views Novo Nordisk's Upcoming Obesity Drug Data To Lay Grounds For Eli Lilly's Tirzepatide
January 19, 2023
From Benzinga
Novartis CEO Refutes Recent Report Of Weighing Options For Ophthalmology, Respiratory Units
January 10, 2023
Tickers
NVS
From Benzinga
3 Biotech Companies to Watch in 2023
January 06, 2023
From InvestorPlace
2 Top Biotech Stocks to Buy Right Now
January 06, 2023
From Motley Fool
GSK Looking For Under-Appreciated M&A Targets, Not Trying To Be Next Roche Or AstraZeneca
December 30, 2022
From Benzinga
2 Cathie Wood Stocks to Buy and Hold Through 2023 and Beyond
December 29, 2022
From Motley Fool
From Benzinga
From Benzinga
5 Value Stocks In The Healthcare Sector
December 26, 2022
From Benzinga
10 Health Care Stocks Whale Activity In Today's Session
December 23, 2022
From Benzinga
3 Ridiculously Cheap Dividend Stocks That Yield More Than 3%
December 22, 2022
From Motley Fool
Top M&A Target: Madrigal Pharmaceuticals Could Be Next After Successful NASH Data, Analyst Says
December 20, 2022
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.